Avalon GloboCare (ALBT) Updates FDA Registration for KetoAir Device
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: Benzinga
- FDA Registration Update: Avalon GloboCare announced the renewal of FDA establishment registration for its KetoAir device, a handheld breathalyzer designed for ketogenic health management that provides real-time breath acetone concentration measurements, enhancing users' ability to monitor fat metabolism effectively.
- Marketing Strategy: The company plans to initiate marketing efforts for KetoAir in Q2 2026, aiming to enhance its marketing and distribution capabilities in both B2B and B2C markets through its subsidiary, Avalon Quantum AI, LLC, which is expected to expand its market presence significantly.
- Stock Performance: As of Wednesday, Avalon GloboCare's stock fell 23.64% to $0.84, trading 31.1% below its 20-day simple moving average, indicating significant bearish momentum, with a 70.51% decline over the past 12 months, positioning the stock closer to its 52-week lows.
- Technical Indicators: The RSI is at 39.65, indicating a neutral state, while the MACD is above its signal line, suggesting a potential bullish trend; this combination of indicators presents mixed momentum for the stock, prompting investors to exercise caution in their assessments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALBT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALBT
About ALBT
Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. The Company operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The Company is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avalon GloboCare (ALBT) Updates FDA Registration for KetoAir Device
- FDA Registration Update: Avalon GloboCare announced the renewal of FDA establishment registration for its KetoAir device, a handheld breathalyzer designed for ketogenic health management that provides real-time breath acetone concentration measurements, enhancing users' ability to monitor fat metabolism effectively.
- Marketing Strategy: The company plans to initiate marketing efforts for KetoAir in Q2 2026, aiming to enhance its marketing and distribution capabilities in both B2B and B2C markets through its subsidiary, Avalon Quantum AI, LLC, which is expected to expand its market presence significantly.
- Stock Performance: As of Wednesday, Avalon GloboCare's stock fell 23.64% to $0.84, trading 31.1% below its 20-day simple moving average, indicating significant bearish momentum, with a 70.51% decline over the past 12 months, positioning the stock closer to its 52-week lows.
- Technical Indicators: The RSI is at 39.65, indicating a neutral state, while the MACD is above its signal line, suggesting a potential bullish trend; this combination of indicators presents mixed momentum for the stock, prompting investors to exercise caution in their assessments.
Continue Reading
GameStop Corp (GME) CEO Ryan Cohen Buys 500,000 Shares, Stock Rises 2.6%
- CEO Stock Purchase: GameStop CEO Ryan Cohen disclosed the purchase of 500,000 shares at an average price of approximately $21.12 per share in an SEC filing, which not only boosts market confidence but may also enhance investor expectations regarding the company's future growth.
- Stock Price Surge: Following this announcement, GameStop's stock rose 2.6% to $21.65 in pre-market trading, indicating a positive market reaction to the company's strategic direction, potentially attracting more investor interest.
- Market Movements: Pineapple Financial saw a dramatic increase of 175.2% to $2.67 in pre-market trading, reflecting market recognition of its first-quarter gross billings of $4.1 million and revenue of $0.7 million, showcasing its future growth potential.
- Other Stock Performances: Anteris Technologies announced plans for a $200 million public offering, resulting in a 26.4% increase in its stock price to $7.27, indicating a positive market response to its capital expansion plans, which may provide funding support for future growth.
Continue Reading